Cleaver, Ph.D. is Director of the Powell Gene Therapy Center (PGTC) and Human Applications Laboratory at the University of Florida. Dr. Cleaver has extensive experience (>10 years) in the FDA - regulated cGMP manufacturing of cellular and gene vector products for use in clinical trials. He has directed Re-MATC H Protocol Page 98 of 106 Version: 20180628 GMP manufacturing of products for use at single -site, multi- site, and even international clinical studies and is an expert in the regulatory compliant manufacturing of GMP materials. Dr. Cleaver and his staff within the PGTC will be responsible for the generation of cellular products used in this protocol a nd the regulatory oversight, record keeping, and release of qualified cellular products for this study. http://www.gtc.ufl.edu/core/gtc -apps.htm http://urology.ufl.edu/about -us/faculty -staff-directory/brian -d-cleaver -phd/ Anthony T. Yachnis, M.D. is Professor of Pathology and Medical Director of Anatomical Pathology at the University of Florida. He is a b oard-certified neuropathologist with over twenty years of clinical experience. In such capacity, he reviews and performs confirmatory diagnosis on all brain tumor specimens collected at University of Florida (>600 annually) and will ensure the pathologic e ligibility criteria for patients enrolled in this study are met. He will also evaluate the histochemical analysis of lymphocytic infiltrates in tumor specimens, and perform all neurotoxicity evaluations. Dr. Yachnis will interact with the study team in the coordination of collection of tumor materials collected at the UF site and will perform the confirmatory diagnostic evaluation of specimens collected from external sites. http://pathlabs .ufl.edu/team/pathologists/yachnis -a William A. Friedman, M.D. (Other Significant Contributor) is Professor and Chairman of Neurosurgery at the University of Florida and Co- Director of the Preston A. Wells, Jr.